Janssen to Develop Bispecific Antibodies based on Zymeworks Platforms in Up-to-$1.4B Deal

Johnson & Johnson’s Janssen Biotech will use Zymeworks’ Azymetric™ and Effector Function Enhancement and Control Technology (EFECT™) platforms to research, develop, and commercialize up to six bispecific antibodies directed to unspecified Janssen therapeutic targets, through a licensing agreement that Zymeworks said today could generate for it up to $1.4 billion-plus.The collaboration is Zymeworks’ sixth with a biopharma giant, and the first since its wholly-own